Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocodone bitartrate + acetaminophen is a fixed-dose combination oral analgesic used to treat moderate to severe pain when alternative treatments are inadequate. Hydrocodone is a semi-synthetic opioid analgesic that acts as a full agonist at the mu-opioid receptor in the central nervous system, providing pain relief and cough suppression. Acetaminophen (paracetamol) is an analgesic and antipyretic agent; its precise mechanism of action remains unclear but likely involves inhibition of prostaglandin synthesis in the CNS. The combination leverages both opioid and non-opioid mechanisms for synergistic pain control. Hydrocodone/acetaminophen was first approved in 1982 in the United States and remains one of the most commonly prescribed opioids for acute pain management[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocodone bitartrate + acetaminophen.